2025/11/22 by Kara A. Johnson, Patricia B. Coutinho, Filipe Sarmento +5 · 1 voice
Medicine · Neuroscience · #Neurological disorders and treatments #Transcranial Magnetic Stimulation Studies #Botulinum Toxin and Related Neurological Disorders
paper · doi:10.1002/mds.70129
openalex publication_date 2025/11/22 · openalex created_date 2025/11/23 · openalex updated_date 2026/06/14
BACKGROUND: Deep brain stimulation (DBS) targeted to the globus pallidus (GP) can effectively alleviate dystonia symptoms. However, identifying optimal therapeutic stimulation parameters is challenging due to the manual programming process and the paucity of acute effects of DBS on dystonia symptoms. OBJECTIVE: This study aimed to investigate evoked resonant neural activity (ERNA) in the GP as a potential biomarker to guide DBS contact selection for chronic therapy in patients with dystonia. METHODS: In n = 8 patients (n = 9 hemispheres) undergoing GP DBS implantation for dystonia, intraoperative local field potential (LFP) recordings were acquired at resting state (30 seconds) and during bursts of high-frequency stimulation delivered from each DBS contact. ERNA features (amplitude, frequency, and number of peaks) were measured and correlated with dystonia symptom severity, resting-state LFP spectral power, and postoperative chronic (12-month) therapeutic stimulation parameters. RESULTS: ERNA was consistently elicited by GP DBS but varied in amplitude, frequency, and number of peaks across individuals and stimulating contacts. Higher ERNA amplitudes were associated with stimulation at the GP internus/externus border. ERNA frequency was negatively correlated with cervical dystonia severity (P < 0.001) and resting-state alpha (8-12 Hz) power (P < 0.05). In eight of nine (88.9%) hemispheres, the DBS contact that elicited the maximum ERNA matched the contact empirically selected for chronic therapy by expert clinicians through routine clinical programming. CONCLUSIONS: Based on its correlation with dystonia symptom severity and therapeutic contact for chronic DBS, ERNA shows promise as an objective candidate biomarker to improve the efficiency and efficacy of DBS for dystonia. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.